February 13, 2023

Study participants with prostate cancer who reported the highest amounts of plant-based foods in their diets had a 52% lower risk of the cancer progressing and a 53% lower risk of recurrence compared to those who had the lowest amounts of plants in their diets. The diet assessments were based on questionnaires of food consumption given to people enrolled in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) study.

February 8, 2023

“ASCO applauds President Biden’s focus on ‘ending cancer as we know it’ during the State of the Union address. We continue to urge the president to keep cancer care and research as top national priorities and are pleased with his plans to advance efforts to strengthen the Cancer Moonshot, improve cancer clinical trials, and foster breakthroughs through the Advanced Research Projects Agency for Health (ARPA-H).”


February 7, 2023

In anticipation of President Biden’s State of the Union Address, the Association for Clinical Oncology (ASCO) is urging the president to keep cancer care and research as top national priorities. 

February 6, 2023

Two prostate cancer studies – one examining the poly(ADP-ribose) polymerase inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide and one on plant-based diets and disease progression – will be highlighted in the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 800 abstracts that will be presented at the Symposium.  

February 2, 2023

Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of the President and the resources of the federal government is essential to our shared goal of accelerating the pace of progress against a disease that will be diagnosed in more than 1.9 million people in the U.S. this year.

January 23, 2023

A non-invasive blood test may help to determine the most effective treatment for patients with advanced gastrointestinal stromal tumors (GIST) that has progressed or is intolerant to first-line imatinib. These results will be presented during the January 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

January 21, 2023

SAN FRANCISCO – Eleven noteworthy studies exploring new approaches in the treatment and management of gastrointestinal cancers will be presented at the 2023 ASCO Gastrointestinal Cancers Symposium, taking place January 19-21, 2023, at the Moscone West Building in San Francisco, California.  

January 11, 2023

Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published today in JCO Oncology Practice.

December 19, 2022

A phase II randomized clinical trial in people with stage IV non-small cell lung cancer (NSCLC) showed that adding a novel, engineered antibody to an immunotherapy resulted in better overall response rates (ORR) and progression-free survival (PFS) compared to treatment with the immunotherapy drug alone.

November 22, 2022

Prior authorization is harming individuals with cancer according to new survey results from the Association for Clinical Oncology (ASCO). The survey found that prior authorization delays necessary care, worsens cancer care outcomes, and diverts clinicians from caring for their patients.

November 15, 2022

The American Society of Clinical Oncology, Inc. (ASCO®) and the European Cancer Organisation (ECO) are pleased to announce a new collaboration, formalized with a recently signed memorandum of understanding, that will advance their shared aims on cancer control. 

November 8, 2022

In the largest study to date of chimeric antigen receptor (CAR) T-cell therapy for relapsed and refractory childhood B-cell acute lymphoblastic leukemia (B-ALL), clinicians in China were able to rapidly produce dual CD19/CD22 targeted T-cells, resulting in treatments that led to undetectable disease in 99% of 194 patients with treatment-resistant or high-risk-of-relapse leukemia, according to a study published today in the Journal of Clinical Oncology. 

October 26, 2022

The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) today released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The statement was published in the AACR’s journal Clinical Cancer Research and ASCO’s Journal of Clinical Oncology.

October 17, 2022

In conjunction with the World Cancer Congress, the American Society of Clinical Oncology, Inc. (ASCO®) is publishing a special series of its online publication JCO Global Oncology focused on innovative, evidence-based models for cancer professionals and patients to improve access to quality cancer care particularly in low- and middle-income countries (LMICs).

October 11, 2022

Alexandria, VA. – Building on its longstanding commitment to health equity, the American Society of Clinical Oncology (ASCO) is launching a multi-year pilot program to increase access to high-quality, equitable cancer care in rural Montana.